Loading peptide directory…
Editorial entries for every peptide we cover — each page links the vendors that carry it, the reviews users have left, and the literature behind it.
Gonadorelin is the native decapeptide gonadotropin-releasing hormone (GnRH). Among the compounds in this report it has the clearest human efficacy track record, because pulsatile dosing directly replaces deficient hypothalamic GnRH in selected patients, most notably women with hypothalamic amenorrhea.
Human chorionic gonadotropin is a placental polypeptide hormone composed of α and β subunits. In the reviewed U.S. label, urinary-derived hCG products are FDA-approved for prepubertal cryptorchidism not due to anatomical obstruction, selected cases of male hypogonadotropic hypogonadism, and induction of ovulation and pregnancy in appropriately pretreated infertile women. The label explicitly states that hCG is not effective adjunctive therapy for obesity.
Kisspeptin-10 is a short active fragment of kisspeptin and functions as a physiologic upstream trigger of GnRH secretion. Its human evidence is compelling at the level of acute endocrine activation, but far less developed for standardized long-term clinical use.
Oxytocin is an endogenous nonapeptide hormone with approved medical use in labor induction, labor augmentation, and postpartum bleeding control (Pitocin). Its sexual-health relevance comes from experimental and translational literature on social bonding, sexual arousal, orgasm, attachment, and pair-related behavior — mostly through intranasal rather than obstetric use.
PT-141 (bremelanotide, brand name Vyleesi) is a nonselective melanocortin receptor agonist and the only peptide in this batch with a current FDA therapeutic label. It is approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts centrally on melanocortin signaling — not as a vasodilator.